Acute angiotensin-converting enzyme inhibition increases the plasma level of the natural stem cell regulator N-acetyl-seryl-aspartyl-lysyl-proline
about
Structural basis of peptide recognition by the angiotensin-1 converting enzyme homologue AnCE from Drosophila melanogasterA modern understanding of the traditional and nontraditional biological functions of angiotensin-converting enzymeN-acetyl-seryl-aspartyl-lysyl-proline prevents cardiac remodeling and dysfunction induced by galectin-3, a mammalian adhesion/growth-regulatory lectinThe Effects of Angiotensin Converting Enzyme Inhibitors (ACE-I) on Human N-Acetyl-Seryl-Aspartyl-Lysyl-Proline (Ac-SDKP) Levels: A Systematic Review and Meta-AnalysisN-acetyl-seryl-aspartyl-lysyl-proline: a valuable endogenous anti-fibrotic peptide for combating kidney fibrosis in diabetesFragment-based design for the development of N-domain-selective angiotensin-1-converting enzyme inhibitorsInterpretable correlation descriptors for quantitativestructure-activity relationshipsLong-term effect of N-acetyl-seryl-aspartyl-lysyl-proline on left ventricular collagen deposition in rats with 2-kidney, 1-clip hypertensionA new antifibrotic target of Ac-SDKP: inhibition of myofibroblast differentiation in rat lung with silicosisRXP 407, a phosphinic peptide, is a potent inhibitor of angiotensin I converting enzyme able to differentiate between its two active sites.Development of an enzyme immunoassay for a stable amidated analog of the hemoregulatory peptide acetyl-Ser-Asp-Lys-Pro.Accelerated hematopoietic recovery with angiotensin-(1-7) after total body radiation.N-acetyl-seryl-aspartyl-lysyl-proline attenuates renal injury and dysfunction in hypertensive rats with reduced renal mass: council for high blood pressure researchAc-SDKP inhibits transforming growth factor-beta1-induced differentiation of human cardiac fibroblasts into myofibroblasts.Angiotensin-converting enzyme N-terminal inactivation alleviates bleomycin-induced lung injury.Novel natural peptide substrates for endopeptidase 24.15, neurolysin, and angiotensin-converting enzyme.Different in vivo functions of the two catalytic domains of angiotensin-converting enzyme (ACE).Captopril and losartan for mitigation of renal injury caused by single-dose total-body irradiation.The peptide network regulated by angiotensin converting enzyme (ACE) in hematopoiesisThe pharmacokinetics and pharmacodynamics of angiotensin-receptor blockers in end-stage renal disease.A novel angiotensin I-converting enzyme mutation (S333W) impairs N-domain enzymatic cleavage of the anti-fibrotic peptide, AcSDKP.N-Acetyl-Seryl-Aspartyl-Lysyl-Proline: mechanisms of renal protection in mouse model of systemic lupus erythematosusRole of N-acetyl-seryl-aspartyl-lysyl-proline in the antifibrotic and anti-inflammatory effects of the angiotensin-converting enzyme inhibitor captopril in hypertensionResistance of dialyzed patients to erythropoietin.Nontraditional roles of angiotensin-converting enzyme.Intense myocyte formation from cardiac stem cells in human cardiac hypertrophy.N-Acetyl-seryl-aspartyl-lysyl-proline inhibits ET-1-induced collagen production by preserving Src homology 2-containing protein tyrosine phosphatase-2 activity in cardiac fibroblasts.Renal protective effect of N-acetyl-seryl-aspartyl-lysyl-proline in dahl salt-sensitive rats.The hematopoietic system: a new niche for the renin-angiotensin system.Treatment with N-acetyl-seryl-aspartyl-lysyl-proline prevents experimental autoimmune myocarditis in ratsCharacterization and localization of Ac-SDKP receptor binding sites using 125I-labeled Hpp-Aca-SDKP in rat cardiac fibroblastsPAI-1 and kidney fibrosis.Prevention of aortic fibrosis by N-acetyl-seryl-aspartyl-lysyl-proline in angiotensin II-induced hypertension.Antihypertensive medications and anemia.Cardiorenal anemia syndrome: do erythropoietin and iron therapy have a place in the treatment of heart failure?Lack of angiotensin II-facilitated erythropoiesis causes anemia in angiotensin-converting enzyme-deficient miceThe critical role of tissue angiotensin-converting enzyme as revealed by gene targeting in mice.Clinical Implication of the Renin-angiotensin-aldosterone Blockers in Chronic Kidney Disease Undergoing Hemodialysis.Elevation of the antifibrotic peptide N-acetyl-seryl-aspartyl-lysyl-proline: a blood pressure-independent beneficial effect of angiotensin I-converting enzyme inhibitorsRenin inhibitors and cardiovascular and renal protection: an endless quest?
P2860
Q24301320-CA4C60FA-9A71-4448-AC83-6C1260DBFF20Q24306614-5954447F-8717-49CF-AB69-906BE3717AA8Q24651908-B1B8D7A8-DF2C-42F5-80FE-F0AA8B886250Q26776514-8E166E42-745C-46EA-9421-C6A887DAC5E4Q27008887-7DE0C516-6BFF-42D7-9B5B-A7F2529A7742Q27679900-F78315AE-D40B-44FC-B0D0-E13557A2D115Q27867880-D6B4F0C9-447B-4A0C-B816-5594596903E7Q28367770-61CF4A36-ACC9-4F98-AE6E-6C3A5B007D34Q28386061-C4A19E63-D103-4897-AD19-25D1002603B4Q30670251-7EBA493B-F8D9-40B2-8CBF-065EC1421C44Q30697376-2D71ED6B-7078-4AB1-9B4D-025F91A7B6BBQ33400329-15E0B0F0-9A91-48EE-AE08-4989AD718217Q33604039-DC98436A-F074-4522-9B61-0FC49C4BD2BFQ33840689-30D676F3-971E-4DD9-988F-34DD1E8084B8Q34086852-C71A56CB-7965-47BA-BD2F-FD1A8B7D0E47Q34167013-0F0E2ADD-61FC-4EA7-BBB6-99F37F1EEFDEQ34786191-CE16BC92-90A7-42CE-A36A-C72D95A405E1Q34822417-A8FDD50C-B590-4194-BB35-53EB60A924EBQ35050809-5E836BA1-64FD-4D60-94B4-06A745A13362Q35065532-E62CFBCC-95A2-400D-B3F4-75A80BA6CCAAQ35088357-FB0E844A-E921-47B8-8BC7-0DBA0C87A5C5Q35622459-BBF9FF70-2DB9-4728-B075-8C9CDEA1919FQ35670580-A628BBBE-EAA2-4AA4-AE07-6C7522F83511Q35694046-48C2FC72-E67F-4892-A0E2-E37C9625D7A2Q35836666-92951983-F339-4C2B-95C6-B0804FB7D7A1Q35918432-EBF66A3D-4287-4DFF-8C72-BCCC1666E9E5Q36282938-62E55848-BA97-4759-B3C4-86905CBA13F1Q36315598-62F18482-5D2A-4061-85C9-DFF9E7372E3EQ36381958-037EE779-6122-4652-A690-12030814C4FBQ36454235-20CE049A-F30F-48F8-BE3A-5CC13CF0E6A9Q36513469-31F4B55D-5ABA-4C9C-AA40-86955D94A358Q36846526-8644F90E-7F2E-4AE7-9044-44C13FC765E6Q36893345-594AE1E0-96A0-4920-B314-784B317FCF8DQ36929360-F8065121-560C-43E5-BC32-2851FF0481CFQ37138777-F4B5CEDD-89E7-406E-8DA8-1AC61ED2DC91Q37271841-74BC9F16-17DD-42D9-BBC8-8B005C9D33D3Q37367283-5F1FD727-C45B-41A6-885C-AB2D78CA3754Q37620992-5B1E36F8-881C-4603-B48E-65DC8E1E54B5Q37962590-CB38CB30-1685-496B-AA82-925301B3966EQ37990796-99540465-BC4C-4482-8330-4039ECBE9A68
P2860
Acute angiotensin-converting enzyme inhibition increases the plasma level of the natural stem cell regulator N-acetyl-seryl-aspartyl-lysyl-proline
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on February 1996
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Acute angiotensin-converting e ...... l-seryl-aspartyl-lysyl-proline
@en
Acute angiotensin-converting e ...... -seryl-aspartyl-lysyl-proline.
@nl
type
label
Acute angiotensin-converting e ...... l-seryl-aspartyl-lysyl-proline
@en
Acute angiotensin-converting e ...... -seryl-aspartyl-lysyl-proline.
@nl
prefLabel
Acute angiotensin-converting e ...... l-seryl-aspartyl-lysyl-proline
@en
Acute angiotensin-converting e ...... -seryl-aspartyl-lysyl-proline.
@nl
P2093
P2860
P356
P1476
Acute angiotensin-converting e ...... l-seryl-aspartyl-lysyl-proline
@en
P2093
A Rousseau
J M Grognet
S Michelet
T T Guyene
P2860
P304
P356
10.1172/JCI118484
P407
P577
1996-02-01T00:00:00Z